[4-(4-Meth-oxy-phen-yl)-8-oxo-3-(phenyl-selan-yl)spiro-[4.5]deca-3,6,9-trien-2-yl]methyl-cyanamide

LaQuze L Morris; Clarisa A Alvarado; Julia M Goncalves; Ravi P Singh; Carl J Lovely; Muhammed Yousufuddin

doi:10.1107/S2414314620000784

[4-(4-Meth-oxy-phen-yl)-8-oxo-3-(phenyl-selan-yl)spiro-[4.5]deca-3,6,9-trien-2-yl]methyl-cyanamide

IUCrdata. 2020 Jan 28;5(Pt 1):x200078. doi: 10.1107/S2414314620000784. eCollection 2020 Jan.

Authors

LaQuze L Morris¹, Clarisa A Alvarado¹, Julia M Goncalves¹, Ravi P Singh², Carl J Lovely², Muhammed Yousufuddin¹

Affiliations

¹ Life and Health Sciences Department, University of North Texas at Dallas, 7400 University Hills Blvd, Dallas, TX 75241, USA.
² Department of Chemistry and Biochemistry, University of Texas at Arlington, 701 S. Nedderman Dr., Arlington, TX 76019, USA.

Abstract

The title compound, C₂₅H₂₂N₂O₂Se, crystallizes in the space group P2₁/c with one mol-ecule in the asymmetric unit. The compound was synthesized by the addition of phenyl-selenyl bromide to a cyanamide. The phenyl-selenyl portion and the cyano group, as well as the ketone functional group in the cyclo-hexa-2,5-dien-1-one portion of the structure, are disordered, with occupancy factors of 0.555 (14) and 0.445 (14).

Keywords: crystal structure; cyanamide; phenylselanyl derivatives; propargylamines; spiro compounds.

Grants and funding

Funding for this research was provided by: Robert A. Welch Foundation (grant No. 4-1362).